Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3
18+
69 sites in AR, AZ, CA +27
What this study is about
This Phase 3 study is testing 5-Fluorouracil in people with esophageal cancer. The primary outcome being measured is Overall Survival (OS) (Cohort 1).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), capecitabine, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), oxaliplatin, zolbetuximab
oral (Oral Tablet), injection (Injection), infusion
Primary: Overall Survival (OS) (Cohort 1), Progression Free Survival (PFS) (Cohort 1 and Cohort 2)
Secondary: Duration of Response (DoR) (Cohort 1 and Cohort 2), Objective Response Rate (ORR) (Cohort 1 and Cohort 2), Overall Survival (OS) (Cohort 1), Overall Survival (OS) (Cohort 2), Pharmacokinetics of rilvegostomig (Cohort 1), Pharmacokinetics of sonesitatug vedotin (Cohort 1 and Cohort 2), Progression Free Survival (PFS) (Cohort 1), Safety and tolerability (Cohort 1 and Cohort 2)